Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
February 20, 2023
On Sunday February 19th, the 36th Assembly of Heads of State and Government of the African Union elected Dr Jean Kaseya, a public health physician from the Democratic Republic of Congo, as the new Director General of the Africa Centres for Disease Control and Prevention (Africa CDC). Dr Kaseya will ...
Blog Post
January 09, 2023
The past year was tumultuous for SDRs, but we’ve now managed to decipher the annual report and extract the must-knows to help you have a more enjoyable experience when you read it! The report covers the first year after the historic allocation of SDR 456 billion ($650 billion) in August 2021 and pro...
Blog Post
December 15, 2022
Dr. Yi-Chun Lo of Taiwan’s Centers for Disease Control and National Taiwan University Hospital joins Javier Guzman to discuss Taiwan’s COVID-19 experience and broader pandemic preparedness and response efforts. Together, they discuss the lessons Taiwan learned from previous outbreaks like SARS, succ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.